Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan Drug Spending Logs 1st Fall in FY2016
September 19, 2017
- MHLW Begins Discussions towards Submission of Bill to Amend Pharma Law in 2019: Official
September 19, 2017
- MHLW to Start Discussions on Pneumovax Vaccination in Post-Transition Period
September 15, 2017
- Chuikyo Working to Craft ICER Yardstick for Pilot CEA Scheme; Shiroiwa Study Leading Candidate among WTP Cost Surveys?
September 14, 2017
- Chuikyo Ponders How to Deal with ICER for Products with Multiple Indications
September 14, 2017
- Samurai Biotech Association Calls for NHI Price Increases When Sales Fall Below Forecasts: Chuikyo
September 14, 2017
- JGA President Sees Reduction in Number of Generic Drug Makers as “Inevitable”: Chuikyo
September 14, 2017
- With 253 Billion Yen Estimate Out, Chuikyo Members Prod MHLW to Vet Impact of Price Maintenance Premium
September 14, 2017
- JPWA Expresses Concern Over Price Renegotiations, Calls for Guidelines to Curb Practice
September 14, 2017
- (Update) Similar “Treatment” Comparison Method Could Be Up for Discussion as New Pricing Scheme: Chuikyo
September 13, 2017
- MHLW to Notify of Criteria for Drugs Subject to Optimal Use Guidelines in Mid-September
September 13, 2017
- Similar “Treatment” Comparison Method Could Be Up for Discussion as New Pricing Scheme: Chuikyo
September 13, 2017
- MHLW Calls for Reduction in Maximum Administration Period and Total Dosage for Feron
September 13, 2017
- MOF Budget Examiner Questions Price Maintenance Premium, Says Its Impact Amounts to Over 253 Billion Yen in FY2017
September 12, 2017
- MHLW to Draft GL on Use of Real World Data in Application Filings to Promote Development of Drugs for Rare Diseases
September 12, 2017
- Kyorin’s Dimethyl Sulfoxide Gets Orphan Status in Japan
September 11, 2017
- MHLW Panel Backs Japan’s 1st PD-L1 Inhibitor, 8-Week Hep C Med and More
September 11, 2017
- Opdivo Clears MHLW Panel for 3rd Line Use in Gastric Cancer, Keytruda to Lose Sakigake Status
September 8, 2017
- Social Security Council Begins Discussion on Basic Policy for FY2018 Reimbursement Reform
September 8, 2017
- MEXT’s FY2018 Budget Request to Include Funding to Build Biobank Network
September 8, 2017
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…